Randall Beckman, DPM
Podiatrist · Houston, TXNPI 1609846328
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (32.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 43 manufacturers reported payments, led by Heron Therapeutics, Inc. at 41.0% of the total. Reporting peaked in 2022 at $48,578 and has fallen 78.0% since, to $10,672 in 2025. Among podiatrist clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 277 payments — averaging $370.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Heron Therapeutics, Inc.$42K
- Vilex LLC$25K
- Stryker$12K
- Linvatec Corporation$6K
- Ortho Solutions Inc$5K
- Ossio Inc$2K
- plus $10K from 37 others
Across 3 payments — averaging $281.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vilex LLC$845
What the payments were for
- Consulting fees$31,08530%
- Speaking & faculty fees$32,90032%
- Travel & lodging$23,51023%
- Food & beverage$10,56910%
- Education$4,2364%
- Entertainment$3680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Zynrelef$41,479
- HINTERMANN$13,054
- SALVATION$9,976
- DYNEX$9,300
- HOFFMANN$6,321
- APONVIE$6,101
- COLINK PLATING SYSTEM$3,966
- TAR$2,302
- NA$2,100
- BioBrace 23mm$1,785
- AUGMENT INJECTABLE$287
- ALLOGRAFT TISSUE$285
- CoLag$148
- Quantum Total Ankle$148
- CoLink$148
- COLINK 2$146
- BIO4$144
- NUZYRA$125
- VersaWrap$124
- SALTO TALARIS TOTAL ANKLE PROSTHESIS$120
How this compares
$102,669 in reported general payments places this provider in the 95th percentile of 470 podiatrist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Colchicine | 37 | $966 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 103 | $937 |
| Terbinafine Hcl | 86 | $822 |
| Ciprofloxacin Hcl | 41 | $738 |
| Clindamycin Hcl | 44 | $690 |
| Ketoconazole | 30 | $621 |
| Gabapentin | 190 | $595 |
| Doxycycline Monohydrate | 21 | $472 |
| Methylprednisolone | 73 | $465 |
| Mupirocin | 56 | $409 |
| Meloxicam | 117 | $406 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 38 | $234 |
| Allopurinol | 32 | $218 |
| Prednisone | 56 | $143 |
| Cefadroxil | 11 | $77 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Houston
- Gary LepowHouston$1M
- Andrew SchneiderHouston$150K
- Jason ArmstrongHouston$91K
- Jerry MilesHouston$58K
- Tina OliverHouston$42K
- Lawrence MactavishHouston$41K
- Roberto de Los SantosHouston$33K
- Randal LepowHouston$33K
- Ava WashkoHouston$19K
- Jeffrey RossHouston$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.